Evaluation of the introduction of buprenorphine – naloxone oro-adhesive film formulation to patients in NHS Lanarkshire

Background. A new combination formulation of buprenorphine-naloxone was approved for use in Scotland. This new preparation offered a different treatment option for patients and prescribers, but the service wanted to determine if patients were satisfied with the new formulation as a treatment option and benefits experienced. Method. Patients already on the existing buprenorphine-naloxone preparation were offered the new formulation for their treatment. Those wishing to be prescribed the new formulation were asked to complete a questionnaire after a minimum of 4 weeks of the new formulation. The questionnaire evaluated the satisfaction levels of the new formulation and a number of other psychosocial aspects. The responses were analysed for any benefits or adverse effects reported. Results. There were several benefits reported by patients from the new formulation, both medical and psychosocial following the change. The benefits included feeling better controlled, quicker dissolution of the medication, improved relationships with family and attendance for other health related issues. Conclusions. The film formulation of buprenorphine-naloxone was well accepted by patients. Patients reported several benefits in comparison to their previous treatment with the sublingual formulation. The film appears to have a welcome role as a new treatment option of opioid use disorder.